Advertisement

Search Results

Advertisement



Your search for all items matches 34077 pages

Showing 401 - 450


bladder cancer

Bladder-Preserving Trimodality Treatment for Recurrent High-Grade T1 Bladder Cancer

As reported in Journal of Clinical Oncology by Dahl et al, a phase II trial (NRG Oncology/RTOG 0926) has shown good outcomes with bladder-preserving trimodality the�rapy for recurrent high-grade T1 bladder cancer among patients in whom bacillus Calmette-Guérin therapy failed. Study Details In the...

Intensified Chemotherapy with Unfavorable Tumor Marker Decline in Poor-Prognosis Germ Cell Tumors: Updated Analysis from of GETUG-13 Trial

In long-term follow-up of the French phase III GETUG-13 trial reported in the Journal of Clinical Oncology, Fizazi et al reported that intensified chemotherapy was associated with significantly better progression-free survival among patients with poor-prognosis nonseminomatous germ cell tumors with ...

lung cancer
issues in oncology

Study Compares Lung Cancer Screening Triage Protocols

The PanCan nodule management protocol may be superior at triaging lung cancer screening participants compared with the LungRADSv1.1 approach, according to new findings presented by McWilliams et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung...

colorectal cancer

Complete Mesocolic Excision vs D2 Dissection for Right-Sided Colon Cancer

As reported in Journal of Clinical Oncology by Lu et al, the Chinese phase III RELARC trial showed no significant improvement in disease-free survival with complete mesocolic excision vs D2 lymph node dissection in patients with right-sided colon cancer. As stated by the investigators, “…[complete...

lung cancer
issues in oncology

Perioperative Nivolumab May Improve Event-Free Survival Compared With Neoadjuvant Nivolumab Plus Chemotherapy Alone in Patients With Resectable NSCLC

Adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery may be effective at reducing the risk of disease recurrence or mortality in patients with resectable non–small cell lung cancer (NSCLC) compared with neoadjuvant nivolumab plus chemotherapy alone, according to new...

lung cancer
issues in oncology

IASLC Global Survey on Biomarker Testing Reveals Progress and Persistent Barriers in Lung Cancer Biomarker Testing

Despite significant improvements in the perception of biomarker testing compared with a 2018 survey, substantial barriers to implementation may persist globally, according to new findings presented by Smeltzer et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World...

lung cancer
issues in oncology
immunotherapy

Pathway to Developing Predictive Biomarkers for Immune Checkpoint Inhibitors in NSCLC

Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors, according to new findings presented by Kulasinghe et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on...

Addition of Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy for Early Breast Cancer

In a meta-analysis reported in JAMA Oncology, Villacampa et al found that the addition of neoadjuvant immune checkpoint inhibitor treatment to chemotherapy was associated with improved outcomes among subgroups of patients with early breast cancer.   Study Details A literature search through...

HRQOL With Capivasertib/Fulvestrant vs Placebo/Fulvestrant in Advanced Breast Cancer: Analysis From CAPItello-291 Trial

As reported in The Lancet Oncology by Oliveira et al, patient-reported outcomes in the phase III CAPItello-291 trial indicate a delay in deterioration of health-related quality of life (HRQOL) with capivasertib/fulvestrant vs placebo/fulvestrant in patients with previously treated hormone...

lung cancer

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small...

lung cancer

Ifinatamab Deruxtecan Shows Activity in Extensive-Stage Small Cell Lung Cancer

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study. The findings were presented at the International Association for...

solid tumors
issues in oncology

Youth E-Cigarette Use May Have Declined to Lowest Level in a Decade

A fewer number of U.S. youths have reported current use of e-cigarettes in 2024 compared with 2023, according to new findings published by Park-Lee et al in the Morbidity and Mortality Weekly Report. Background E-cigarettes and nicotine pouches are two categories of tobacco products the U.S. Food...

lung cancer

Addition of Pembrolizumab to Chemotherapy in EGFR TKI-Resistant, EGFR-Mutant, Metastatic Nonsquamous NSCLC

As reported in the Journal of Clinical Oncology by Yang et al, the phase III KEYNOTE-789 trial has shown no significant improvement in progression-free or overall survival with the addition of pembrolizumab to pemetrexed/platinum in EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant...

prostate cancer
issues in oncology

High Proportion of U.S. Men Older Than 45 Years May Have Misconceptions About Prostate Cancer Screening as Rates of Late-Stage Diagnoses Continue to Rise

Investigators have uncovered misconceptions and gaps in awareness regarding prostate cancer and screening guidelines in light of Prostate Cancer Awareness Month in September, according to a recent survey conducted by The Harris Poll. Background In 2024, an estimated 299,010 men will be diagnosed...

lung cancer

Artificial Intelligence Method Transforms Gene Mutation Prediction in Lung Cancer

Research suggests an artificial intelligence (AI) tool called DeepGEM may provide an advancement in genomic testing that offers an accurate, cost-effective, and timely method for gene mutation prediction from histopathology slides. The research was presented at the International Association for the ...

multiple myeloma
lymphoma

FDA Approves Ready-to-Use Version of Bortezomib for Subcutaneous Administration

The U.S. Food and Drug Administration (FDA) has approved a new presentation of bortezomib (Boruzu) for ready-to-use subcutaneous or intravenous administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. Bortezomib, a...

pancreatic cancer
issues in oncology

How Accurate Is Staging in Early Pancreatic Cancer?

Staging may be inaccurate in up to 80% of patients with early pancreatic cancer, according to a recent study published by Perrotta et al in JAMA. The findings underscored the need for advancements in diagnostic technology and staging, which may help to improve early pancreatic cancer treatment and...

colorectal cancer
gastroesophageal cancer
pancreatic cancer
issues in oncology

Omitting 5-FU Bolus May Reduce Side Effects in Patients With Gastrointestinal Cancers

Investigators have found that administering fluorouracil (5-FU) through continuous infusion and omitting the bolus component in patients undergoing commonly used treatment regimens targeting metastatic gastrointestinal cancers may improve tolerability without reducing treatment efficacy or...

breast cancer
genomics/genetics

Study Supports Universal Genetic Testing of Newly Diagnosed Patients With Invasive Breast Cancer

In a cross-sectional study reported in JAMA Network Open, Rezoug et al found that universal genetic testing identified immediately actionable and established germline pathogenic variants in more than 1 in 20 newly diagnosed patients with invasive breast cancer and was associated with systemic...

prostate cancer

Prostate Cancer Mortality and 5-ARI Use

In a Canadian study reported in JAMA Network Open, Hamilton et al found that use of 5-alpha reductase inhibitors (5-ARIs) prior to the diagnosis of prostate cancer was not associated with an increased risk of prostate cancer–specific or overall mortality. Study Details The study involved data from...

geriatric oncology

Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults

Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...

breast cancer

A Diagnosis of Triple-Negative Breast Cancer Was Not on My Radar

Despite the fact that there is no history of breast cancer in my family, I didn’t take that good fortune for granted and was diligent about getting my regularly scheduled mammograms and clinical breast exams, which never found any hint of disease. So, it was especially frightening when, while on a...

cardio-oncology
lymphoma

New Studies Explore Relationships Between Heart Failure and Lymphoma, Arterial Thromboembolism and Cancer

In two studies recently reported in JACC: CardioOncology, Upshaw and colleagues1 examined the impact of preexisting heart failure on mortality in older patients in the United States with newly diagnosed Hodgkin lymphoma, and Gon and colleagues2 analyzed the incidence and impact of arterial...

IDEA Awardees

Khalid El Bairi, MDFaculty of Medical SciencesUniversity of Mohammed VI PolytechnicBen Guerir, Morocco Myriam Saadi, MDMedical OncologyAbderrahmen Mami Hospital of ArianaTunis, Tunisia Karishma Sharma, MDDepartment of Hematology and OncologyAga Khan University HospitalNairobi, Kenya Matheus...

global cancer care

IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting

It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...

breast cancer

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phase III ALEXANDRA/IMpassion030 trial. The results were presented at the 2024 European Breast Cancer...

colorectal cancer

Addition of Oxaliplatin to Fluoropyrimidine/Bevacizumab in Initial Therapy for Metastatic Colorectal Cancer in Older Patients

In a Japanese phase III trial (JCOG1018) reported in the Journal of Clinical Oncology, Takashima et al found that adding oxaliplatin to fluoropyrimidine/bevacizumab did not improve progression-free survival in the initial treatment of older patients with unresectable metastatic colorectal cancer....

bladder cancer

Sacituzumab Govitecan in Cisplatin-Ineligible Advanced Urothelial Cancer After ICI Therapy

In cohort 2 of the phase II TROPHY-U-01 study, reported in the Journal of Clinical Oncology, Petrylak et al found that sacituzumab govitecan-hziy was active in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer progressing after immune checkpoint inhibitor (ICI)...

solid tumors
issues in oncology
cardio-oncology

Liquid Biopsy May Predict Risk of Venous Thromboembolism in Patients With Cancer

Researchers have found that a liquid biopsy may help to predict whether patients with cancer may be at risk of developing venous thromboembolism, according to a recent study published by Jee et al in Nature Medicine. Background Liquid biopsy tests—such as MSK-ACCESS—increasingly play a role in...

immunotherapy
issues in oncology

Can AI Tool Improve Detection of Immune-Related Adverse Events in Patients With Cancer?

Researchers have explored whether an artificial intelligence (AI)-based tool could help to detect immune-related adverse events in patients with cancer, according to a recent study published by Sun et al in the Journal of Clinical Oncology. Background Although immune checkpoint inhibitors can...

cardio-oncology

Immune Checkpoint Inhibitor–Related Cardiotoxicity in Patients With Cancer

In a meta-analysis reported in JAMA Oncology, Nielsen et al estimated the risk of cardiotoxicity associated with immune checkpoint inhibitor (ICI) treatment of cancers. Study Details The meta-analysis included 83,315 unique patients in 589 unique trials of ICIs and ICI combination therapies. The...

solid tumors

Fam-Trastuzumab Deruxtecan-nxki in Unresectable or Metastatic HER2-Positive Solid Tumors

On April 5, 2024, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted accelerated approval for adults with unresectable or metastatic HER2-positive (immunohistochemistry 3+) solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.1 Supporting...

bladder cancer

Nivolumab in Combination With Cisplatin Plus Gemcitabine in Treatment of Unresectable or Metastatic Urothelial Carcinoma

Nivolumab (Opdivo) was approved for use in combination with cisplatin and gemcitabine for first-line treatment of patients with unresectable or metastatic urothelial carcinoma.1 Supporting Efficacy Data Approval was based on the open-label CheckMate 901 trial ­(ClinicalTrials.gov identifier...

supportive care

New Collaborative Guideline Highlights the Importance of Multidisciplinary Care for Patients With Osteoradionecrosis

A joint guideline from the International Society of Oral Oncology–Multinational Association for Supportive Care in Cancer and ASCO seeks to fill a gap in the clinical guidance for patients with head and neck cancers who develop osteoradionecrosis following their head and neck radiation therapy.1...

bladder cancer

Nivolumab Plus Chemotherapy Extends Survival in Lymph Node–Only Metastatic Urothelial Cancer

The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of...

head and neck cancer

Chinese Study Finds Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer

Nasopharyngeal carcinoma is an aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is less than 1 per 100,000 in Europe, the United States, and the Pacific,1 data from the International Agency...

cns cancers
issues in oncology

Mobile Phones May Not Be Linked to Brain Cancer, WHO-Backed Study Finds

Investigators have found that there may not be an association between mobile phone use and an increased risk of brain cancer, according to a recent World Health Organization (WHO)-commissioned review published by Karipidis et al in Environmental International.    Background The WHO and other...

colorectal cancer
issues in oncology

New Study Illuminates Variations in Performance Characteristics Between FIT Tests

Researchers have found substantial variations in the performance characteristics of five commonly used fecal immunochemical tests (FIT), according to a recent study published by Levy et al in the Annals of Internal Medicine. Background Stool-based tests like FIT are currently recommended for...

kidney cancer

Belzutifan vs Everolimus in Previously Treated Advanced Renal Cell Carcinoma

As reported in The New England Journal of Medicine by Choueiri and colleagues, the phase III LITESPARK-005 trial has shown improved progression-free survival with the hypoxia-inducible factor–2α inhibitor belzutifan vs everolimus in previously treated patients with advanced clear-cell renal cell...

multiple myeloma

Delays in Oral Antimyeloma Treatment Initiation: Role of Social Determinants of Health

A retrospective cohort study published in Blood Cancer Journal by Gasoyan et al revealed discrepancies between the timing of the initiation of any treatment and the fill of prescriptions for oral antimyeloma medications in patients with multiple myeloma, with a lower likelihood of Black and older...

breast cancer

Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...

global cancer care

Prescription for Progress: Lancet Oncology Commission’s Practical Strategies for Global Cancer Surgery

In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...

head and neck cancer
immunotherapy

Recurrent or Metastatic HNSCC: Overall Survival With Immunotherapy

In a study reported in JAMA Network Open, Sun et al analyzed survival outcomes with immune checkpoint inhibitor (ICI) treatment used in first- or second-line therapy, with treatment continuation vs discontinuation, and with treatment rechallenge in patients with recurrent or metastatic head and...

breast cancer
issues in oncology

Effect of False-Positives on Adherence to Subsequent Breast Cancer Screening

Patients may be less likely to return for subsequent screening mammography following a false-positive recall for additional imaging or biopsy, according to a recent study published by Miglioretti et al in the Annals of Internal Medicine. The findings raised concerns regarding the potential...

lung cancer
issues in oncology

Chronic Conditions Could Delay Lung Cancer Diagnoses

Investigators have revealed that patients with certain chronic conditions may face delays in being diagnosed with lung cancer, according to a recent study published by Rogers et al in the British Journal of Cancer. Background Lung cancer is currently one of the leading causes of cancer-related...

gynecologic cancers

Menopausal Hormone Therapy and Risk of Ovarian and Endometrial Cancers

In a long-term follow-up of Women’s Health Initiative (WHI) randomized trials reported in the Journal of Clinical Oncology, Rowan T. Chlebowski, MD, PhD, and colleagues identified risks of ovarian and endometrial cancers associated with the use of menopausal hormone therapy. Study Details The...

breast cancer

T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy

In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In...

skin cancer

Adjuvant Pembrolizumab vs Placebo in Stage III Melanoma: Long-Term Health-Related Quality of Life

In an analysis from the phase III EORTC 1325-MG/KEYNOTE-054 trial reported in The Lancet Oncology, Bührer et al found that adjuvant pembrolizumab was not associated with significant differences in long-term health-related quality of life (HRQOL) compared with placebo in patients with stage III...

supportive care

Oral Cannabis Extract for Refractory Chemotherapy-Induced Nausea and Vomiting

In an Australian phase II/III trial reported in the Journal of Clinical Oncology, Grimison et al found that oral cannabis extract improved the antiemetic complete response rate vs placebo in patients with cancer who had refractory chemotherapy-induced nausea and vomiting (CINV) despite use of...

colorectal cancer

Early-Onset Colorectal Cancer: Rurality and Poverty May Be Linked to Lower Survival

Patients with early-onset colorectal cancer living in rural vs urban areas were found to have a lower likelihood of 5-year survival, with persistent poverty compounding this association in some age groups, according to an analysis published in a research letter by Tsai et al in JAMA Network Open....

Advertisement

Advertisement




Advertisement